Automated Device for Asthma Monitoring and Management in Monitoring Adults With Lung Cancer Undergoing Radiation Therapy

A Pilot Study Investigating the Feasibility of ADAMM (Automated Device for Asthma Monitoring and Management) in Combination With Electronic Patient-Reported Outcomes in Adult Patients With Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03340714

Enrollment

Registered

2017-11-13

Start date

2018-03-20

Completion date

2023-09-25

Last updated

2025-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Carcinoma

Brief summary

This pilot early phase I trial studies the Automated Device for Asthma Monitoring and Management in monitoring adult patients with lung cancer who are undergoing radiation therapy. The Automated Device for Asthma Monitoring and Management may provide useful information to doctors to help monitor adult patients with lung cancer and diagnose certain conditions earlier than traditional means.

Detailed description

PRIMARY OBJECTIVES: I. Determine compliance with the Automated Device for Asthma Monitoring and Management (ADAMM) device in patients receiving radiation therapy (RT) for lung cancer. SECONDARY OBJECTIVES: I. Evaluate feasibility of recruitment, acceptability of the ADAMM device, and compliance with electronic patient-reported outcomes (ePROs) in this patient population

Interventions

DEVICEMonitoring Device

Wear ADAMM

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients are capable of giving informed consent * Patients are eligible to be treated with RT and plan to start treatment * Patients have either metastatic or non-metastatic lung cancer as defined in history and physical * Patients must be able to read or speak English * Women of reproductive potential should have a negative serum or urine pregnancy test within one week prior to radiation planning CT scan

Exclusion criteria

* Patients who cannot read or speak English * Patients who are not candidates for RT treatment * Women of childbearing potential who are pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Percentage of hours per day that patients wear the Automated Device for Asthma Monitoring and Management device	Up to 4 weeks post-radiation therapy	The compliance rate along with a one-sided exact 95% confidence interval will be estimated.
Percentage of days per study period that patients wear the Automated Device for Asthma Monitoring and Management device	Up to 4 weeks post-radiation therapy	The compliance rate along with a one-sided exact 95% confidence interval will be estimated.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026